Results 151 to 160 of about 141,545 (201)
Some of the next articles are maybe not open access.
DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry, 2015DNA methyltransferases (DNMTs) catalyze the methylation at cytosine-C5 mainly in a CpG dinucleotide context. Although DNA methylation is essential for fundamental processes like embryonic development or differentiation, aberrant expression and/or activities of DNMTs are involved in several pathologies, from neurodegeneration to cancer. DNMTs inhibition
ZWERGEL, CLEMENS +2 more
openaire +2 more sources
Epigenetic cancer therapies: DNA methyltransferase inhibitors
Expert Opinion on Investigational Drugs, 2002Human cancers frequently show altered patterns of DNA methylation, particularly at CpG islands. These CpG islands are sequences of DNA rich in CpG dinucleotides and are often found close to gene promoters. Methylation within islands has been shown to be associated with transcriptional repression of the linked gene.
Gordon, Strathdee, Robert, Brown
openaire +3 more sources
DNA Methyltransferase Inhibitors for Cancer Therapy
The Cancer Journal, 2007Aberrant DNA methylation patterns, including hypermethylation of tumor suppressor genes, have been described in many human cancers. These epigenetic mutations can be reversed by DNA methyltransferase inhibitors, which provide novel opportunities for cancer therapy.
Bodo, Brueckner, Dirk, Kuck, Frank, Lyko
openaire +2 more sources
DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry, 2019Aberrant DNA methylation at the 5-position of cytosine, catalyzed by DNA methyltransferases (DNMTs), is associated with not only various cancers by silencing of tumor suppressor genes but also other diseases. The DNMTs, especially the DNMT1, DNMT3A and DNMT3B, are often overexpressed in various cancer tissues and cell lines.
Zehao, Zhou, Huan-Qiu, Li, Feng, Liu
openaire +2 more sources
DNA Methyltransferase Inhibitors
2007Regional hypermethylation and global hypomethylation coexist in cancer cells. Under-standing the mechanisms responsible for global hypomethylation and regional hypermethylation in cancer is required for the proper design of therapeutic strategies targeting the DNA methylation machinery.
Gregory K. Reid, A. Robert MacLeod
openaire +1 more source
Improving cancer immunotherapy with DNA methyltransferase inhibitors
Cancer Immunology, Immunotherapy, 2015Immunotherapy confers durable clinical benefit to melanoma, lung, and kidney cancer patients. Challengingly, most other solid tumors, including ovarian carcinoma, are not particularly responsive to immunotherapy, so combination with a complementary therapy may be beneficial.
Mohammad H, Saleh +2 more
openaire +2 more sources
DNA methyltransferase inhibitor alleviates bleomycin-induced pulmonary inflammation
International Immunopharmacology, 2020Acute lung injury (ALI) is a severe disease characterized by several inflammatory responses in the lung with high mortality. We applied a mouse model of the pulmonary inflammation induced by the intratracheal instillation of bleomycin which is widely used to induce ALI and fibrosis in animal models. We hypothesized that DNA methyltransferase inhibitor,
Chun-Hao, Lu +5 more
openaire +2 more sources
DNA Methyltransferase Inhibitors: Development and Applications
2016As described in previous chapters of this book, DNA methylation is involved in numerous biological processes, and modulation of the activity of DNA methyltransferases (DNMTs) is a powerful strategy to modulate, restore, or reduce DNA methylation.
Lopez, Marie +2 more
openaire +3 more sources
Inhibitors of DNA Methyltransferases: Insights from Computational Studies
Current Medicinal Chemistry, 2012DNA methyltransferases (DNMTs) are a family of epigenetic enzymes for which inhibition is an attractive strategy for the treatment of cancer and other diseases. In synergy with experimental approaches, computational methods are increasingly being used to identify and optimize the activity of inhibitors of DNMTs as well as to rationalize at the ...
J, Yoo, J L, Medina-Franco
openaire +2 more sources
DNA methyltransferase inhibitors in myelodysplastic syndrome
Best Practice & Research Clinical Haematology, 2004Myelodysplastic syndrome (MDS) resulting from a clonal stem cell is a heterogeneous disease that complicates therapeutic decisions. Most patients are of advanced age with attendant comorbities, making treatment choices difficult. Current treatment options include bone marrow transplant, which appears to be the only curative option, and supportive care.
openaire +2 more sources